Literature DB >> 25283086

Roles of obese-insulin resistance and anti-diabetic drugs on the heart with ischemia-reperfusion injury.

Nattayaporn Apaijai1, Siriporn C Chattipakorn, Nipon Chattipakorn.   

Abstract

The incidence of obesity with insulin resistance is increasing worldwide. This condition is also known as a risk factor of coronary artery disease and associated with increased arrhythmias, impaired left ventricular function, and increased infarct size during cardiac ischemia-reperfusion (I/R) injury. The proposed mechanisms are due to impaired glucose utilization and pro-survival signaling molecules, and increased inflammatory cytokines, which have been demonstrated in the I/R hearts in various models of obese-insulin resistance. However, the cardiac effects of diets in the I/R heart are still unsettled since several studies reported that high-caloric diet consumption might protect the heart from I/R injury. Although several therapeutic strategies such as anti-diabetic drugs, natural compounds as well as treadmill exercise have been proposed to exert cardioprotection in the I/R heart in obese-insulin resistant animals, some interventions including ischemic post-conditioning failed to protect the heart from I/R injury. In this comprehensive review, reports from both genetic deletion and dietary-induced obese-insulin resistant animal models regarding the effects of obese-insulin resistance on metabolic parameters, cardiac function, infarct size, and molecular mechanisms under I/R injury are summarized. Moreover, the effects of anti-diabetic drugs and other pharmacological interventions on these parameters in an obese-insulin resistant model under I/R injury are also comprehensively summarized and discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25283086     DOI: 10.1007/s10557-014-6553-6

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  4 in total

1.  Reduced salivary amylase activity in metabolic syndrome patients with obesity could be improved by treatment with a dipeptidyl peptidase IV inhibitor.

Authors:  Jitjiroj Ittichaicharoen; Arintaya Phrommintikul; Nipon Chattipakorn; Siriporn Chattipakorn
Journal:  Clin Oral Investig       Date:  2018-03-08       Impact factor: 3.573

2.  Therapeutic potential of a single-dose melatonin in the attenuation of cardiac ischemia/reperfusion injury in prediabetic obese rats.

Authors:  Kodchanan Singhanat; Nattayaporn Apaijai; Natticha Sumneang; Chayodom Maneechote; Busarin Arunsak; Titikorn Chunchai; Siriporn C Chattipakorn; Nipon Chattipakorn
Journal:  Cell Mol Life Sci       Date:  2022-05-19       Impact factor: 9.261

3.  Gut microbiota regulates cardiac ischemic tolerance and aortic stiffness in obesity.

Authors:  Micah L Battson; Dustin M Lee; Lance C Li Puma; Kayl E Ecton; Keely N Thomas; Hallie P Febvre; Adam J Chicco; Tiffany L Weir; Christopher L Gentile
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-09-27       Impact factor: 4.733

4.  Myocardial susceptibility to ischaemia/reperfusion in obesity: a re-evaluation of the effects of age.

Authors:  I Webster; R Salie; E Marais; W-J Fan; G Maarman; B Huisamen; A Lochner
Journal:  BMC Physiol       Date:  2017-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.